BIIB021

Generic Name
BIIB021
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H15ClN6O
CAS Number
848695-25-0
Unique Ingredient Identifier
851B9FQ7Q0
Background

BIIB021 has been investigated for the treatment of Tumors and Lymphoma.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: BIIB021
Drug: exemestane (Aromasin)
First Posted Date
2009-10-29
Last Posted Date
2015-10-02
Lead Sponsor
Biogen
Target Recruit Count
54
Registration Number
NCT01004081
Locations
🇷🇺

Research Site, St. Petersburg, Russian Federation

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

Phase 2
Completed
Conditions
GIST
Interventions
Drug: BIIB021
First Posted Date
2008-02-20
Last Posted Date
2015-10-02
Lead Sponsor
Biogen
Target Recruit Count
20
Registration Number
NCT00618319
Locations
🇺🇸

Research Site, Santa Monica, California, United States

🇺🇸

Reseach Facility, San Antonio, Texas, United States

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: BIIB021
First Posted Date
2008-02-20
Last Posted Date
2016-12-29
Lead Sponsor
Biogen
Target Recruit Count
68
Registration Number
NCT00618735
Locations
🇺🇸

Research Site, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy